LongevityNCT07456449
Collagen Peptides and Cellular Aging
A study testing Collagen peptides in people with Longevity and Healthy Aging, run by University of Vienna at 1 site in Austria.
Trial summary
The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease). Read more about this study
- Who is it for?
- Ages 50 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Longevity, Healthy Aging, Biological Ageing
- What is being tested?
- Collagen peptides
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 125 participants
- Where
- 1 siteAustria
- Study dates
- 22 Apr 2026to Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 50-70 years; both male and female participants are eligible
- Body mass index (BMI) 25-30 kg/m²
- Low to moderate physical activity: not meeting current WHO recommendations (<150 minutes/week) or ≤2 sessions/week structured training
- Able to live independently and mobile in daily life
- No regular resistance training within the past 6 months
- Provision of written informed consent
Who cannot join
- Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)
- Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)
- Acute infections or surgeries within the last 3 months
- Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)
- Participation in another clinical study within the last 3 months
- Vegetarian or vegan diet (product contains animal-derived collagen)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
University of Vienna, NuTraLab
Vienna, State of Vienna, 1070
Jana Schneider, +43-1-9909194-200, jana.schneider@univie.ac.at
About this study
Official title: Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults
The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).
Main questions it aims to answer are:
Read more
Does six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?
Researchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.
Participants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation/redox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.
- Conditions
- Longevity, Healthy Aging, Biological Ageing
- Being tested
- Collagen peptides, Maltodextrin (Placebo)
- Keywords
- Aging, Collagen, Supplements, Patient Care, Healthspan, Cellular aging
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collagen peptidesDietary supplement
Collagen peptides (oral daily supplementation), taken once daily for 24 weeks in a randomized 1:1, double-blind design; primary outcomes: telomere length (qPCR T/S) and telomerase activity (TRAP), with inflammatory/redox markers as secondary endpoints.
Target population: adults 50-70 years with BMI 25-30 and low-to-moderate activity; vegetarians/vegans excluded due to animal-derived collagen.
Matched maltodextrin placebo, identical dosing and visit schedule (T0, T1, T2), serving as the comparator to isolate collagen peptide effects in the parallel-group, double-blind trial.
Products are approved as foods; prior clinical studies reported no substance-related adverse effects.
Maltodextrin (Placebo)Dietary supplement
Placebo instead of the collagen peptides
| Study group | Role | What they receive |
|---|---|---|
| Collagen Peptides | Experimental | Participants receive daily oral supplementation with specific collagen peptides for 24 weeks. Allocation is randomized 1:1 and double-blinded against placebo. Study visits occur at baseline (T0), 3 months (T1), and 6 months (T2). Blood samples are collected to assess telomere length (qPCR T/S ratio) and telomerase activity (TRAP), alongside inflammation and redox markers. Body composition (bioelectrical impedance), functional tests (muscle strength, mobility), and questionnaires on health and vitality are also performed. The intervention aims to test whether six months of collagen peptides stabilize or extend telomeres and increase telomerase activity compared with placebo. Receives: Dietary Supplement: Collagen peptides |
| Maltodextrin | Placebo comparator | Participants receive a daily placebo matched in a double-blind design for 24 weeks, with the same schedule of study visits at T0, T1, and T2 and the same assessments (blood biomarkers of telomere biology, inflammation/redox; body composition; functional tests; questionnaires) as the verum arm. Maltodextrin serves as the control to compare effects against collagen peptides in a randomized, double-blind, placebo-controlled, parallel-group trial. Receives: Dietary Supplement: Maltodextrin (Placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Telomere length
Changes in leukocyte telomere length (qPCR) from peripheral blood
Measured: Baseline and after supplementation (24 weeks)
Telomerase Activity
Changes telomerase activity measured via TRAP Assay from peripheral blood
Measured: Baseline and at the end of supplemention (24 weeks)
Change from baseline in DNA-oxidation markers
Change in DNA Damage measured through comet assay
Measured: Baseline and at the end of supplementation (24 weeks)
Change from baseline in micronuclei
Change in Micronulei measured through CBMN-Assay
Measured: Baseline and at the end of supplementation (24 weeks)
Secondary outcomes (14)
Change from baseline in Inflammatory markers
Changes in plasma concentrations of interleukins like IL-6, IL-10, TNF-alpha
Measured: Baseline and at the end of supplemention (24 weeks)
Change from baseline in the redox/antioxidant status
Change in superoxide dismutase and glutathione peroxidase via enzymatic tests to assess oxidative stress
Measured: Baseline and at the end of supplementation (24 weeks)
Change from baseline in body composition
Change in fat-free mass and fat mass in kg by bioelectrical impedance
Measured: Basline, after 3 months and at the end of the supplementation (24 weeks)
Change from baseline metabolic markers
Change in serum lipid profile and fasting glucose in mg/dL
Measured: Baseline and at the end of supplementation (24 weeks)
Change from baseline in hormonal markers
Change in serum IGF-1and DHEA in ng/mL measured through immunoassays
Measured: Baseline and at the end of supplementation (24 weeks)
Change from baseline in muscle strength
Change in maximal handgrip and leg strength assessed by dynamometry and leg press
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in dietary intake
Change in dietary intake from standardized 3-day food records to contextualize biomarker and functional outcomes
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like quality of life
Change in health-related quality of life, measured through WHOQOL questionnaire
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change of phase angle
Change in phase angle by bioelectrical impedance
Measured: Basline, after 3 months and at the end of the supplementation (24 weeks)
Change from baseline in Insulin
Measured: Baseline and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like sleep quality
Change in health-related sleep quality meausred through Pittsburgh Sleep Quality Index questionnaire
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like health
Change in health measured through PHQ-9 questionnaire
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like fatigue
Change in health- related outcomes like fatigue measured through FAS questionnaire
Measured: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in oxidative stress
Change in glutathione (GSH) and glutathione disulfide (GSSG)
Measured: Baseline and at the end of supplementation (24 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start22 Apr 2026
- Primary completionFeb 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LongevityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Interventional Study Model: Parallel Assignment - randomized, double-blind, placebo-controlled trial with two parallel groups (collagen peptides vs. placebo) in a 1:1 allocation
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Collagen Research Institute
- Responsible party
- Principal investigator, Daniel König, University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07456449
- Sponsor's protocol ID
- 01400
- Other IDs
- Gelita-AG
- Status last verified
- Jan 2026
- First submitted
- 23 Feb 2026
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults
- ClinicalTrials.gov ID
- NCT07456449
- Acronym / sponsor ID
- 01400
- Conditions
- Longevity, Healthy Aging, Biological Ageing
- Keywords
- Aging, Collagen, Supplements, Patient Care, Healthspan, Cellular aging
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- University of ViennaUniversity, hospital or other
- Collaborators
- Collagen Research Institute
- Study start
- 22 Apr 2026 (actual)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).
Main questions it aims to answer are:
Does six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?
Researchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.
Participants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation/redox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Interventional Study Model: Parallel Assignment - randomized, double-blind, placebo-controlled trial with two parallel groups (collagen peptides vs. placebo) in a 1:1 allocation
| Arm | Type | Receives |
|---|---|---|
| Collagen Peptides | Experimental | Dietary Supplement: Collagen peptidesParticipants receive daily oral supplementation with specific collagen peptides for 24 weeks. Allocation is randomized 1:1 and double-blinded against placebo. Study visits occur at baseline (T0), 3 months (T1), and 6 months (T2). Blood samples are collected to assess telomere length (qPCR T/S ratio) and telomerase activity (TRAP), alongside inflammation and redox markers. Body composition (bioelectrical impedance), functional tests (muscle strength, mobility), and questionnaires on health and vitality are also performed. The intervention aims to test whether six months of collagen peptides stabilize or extend telomeres and increase telomerase activity compared with placebo. |
| Maltodextrin | Placebo comparator | Dietary Supplement: Maltodextrin (Placebo)Participants receive a daily placebo matched in a double-blind design for 24 weeks, with the same schedule of study visits at T0, T1, and T2 and the same assessments (blood biomarkers of telomere biology, inflammation/redox; body composition; functional tests; questionnaires) as the verum arm. Maltodextrin serves as the control to compare effects against collagen peptides in a randomized, double-blind, placebo-controlled, parallel-group trial. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults aged 50-70 years; both male and female participants are eligible
- Body mass index (BMI) 25-30 kg/m²
- Low to moderate physical activity: not meeting current WHO recommendations (<150 minutes/week) or ≤2 sessions/week structured training
- Able to live independently and mobile in daily life
- No regular resistance training within the past 6 months
Key exclusion criteria (6 listed)
- Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)
- Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)
- Acute infections or surgeries within the last 3 months
- Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)
- Participation in another clinical study within the last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collagen peptidesCollagen peptides (oral daily supplementation), taken once daily for 24 weeks in a randomized 1:1, double-blind design; primary outcomes: telomere length (qPCR T/S) and telomerase activity (TRAP), with inflammatory/redox markers as secondary endpoints. Target population: adults 50-70 years with BMI 25-30 and low-to-moderate activity; vegetarians/vegans excluded due to animal-derived collagen. Matched maltodextrin placebo, identical dosing and visit schedule (T0, T1, T2), serving as the comparator to isolate collagen peptide effects in the parallel-group, double-blind trial. Products are approved as foods; prior clinical studies reported no substance-related adverse effects. | Dietary supplement | Collagen Peptides |
| Maltodextrin (Placebo)Placebo instead of the collagen peptides | Dietary supplement | Maltodextrin |
Primary outcome
Telomere length
Time frame: Baseline and after supplementation (24 weeks)
Changes in leukocyte telomere length (qPCR) from peripheral blood
Telomerase Activity
Time frame: Baseline and at the end of supplemention (24 weeks)
Changes telomerase activity measured via TRAP Assay from peripheral blood
Change from baseline in DNA-oxidation markers
Time frame: Baseline and at the end of supplementation (24 weeks)
Change in DNA Damage measured through comet assay
Change from baseline in micronuclei
Time frame: Baseline and at the end of supplementation (24 weeks)
Change in Micronulei measured through CBMN-Assay
14 secondary outcomes
Change from baseline in Inflammatory markers
Time frame: Baseline and at the end of supplemention (24 weeks)
Change from baseline in the redox/antioxidant status
Time frame: Baseline and at the end of supplementation (24 weeks)
Change from baseline in body composition
Time frame: Basline, after 3 months and at the end of the supplementation (24 weeks)
Change from baseline metabolic markers
Time frame: Baseline and at the end of supplementation (24 weeks)
Change from baseline in hormonal markers
Time frame: Baseline and at the end of supplementation (24 weeks)
Change from baseline in muscle strength
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in dietary intake
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like quality of life
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change of phase angle
Time frame: Basline, after 3 months and at the end of the supplementation (24 weeks)
Change from baseline in Insulin
Time frame: Baseline and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like sleep quality
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like health
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in patient-reported outcomes like fatigue
Time frame: Baseline, after 3 months and at the end of supplementation (24 weeks)
Change from baseline in oxidative stress
Time frame: Baseline and at the end of supplementation (24 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Individual participant dataSharing planned: No
Related trials for Longevity
Active, not recruiting
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
Skin Ageing, Healthy Ageing
Not yet recruitingPhase 1
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
Aging, Longevity
Active, not recruiting
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
Healthy Ageing, Protein Supplementation
Not yet recruiting
3D-Printed Versus CAD/CAM-Milled Resin Restorations in Posterior Teeth.
Dental Restorations Longevity
Active, not recruitingObservational study
Longevity Families of the Netherlands
Longevity, Familial Longevity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collagen peptides in people with Longevity and Healthy Aging, run by University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel König, Univ. Prof. Dr. (+43-1-4277-59130, daniel.koenig@univie.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Telomere length (time frame: Baseline and after supplementation (24 weeks)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026; AzTrials last refreshed its copy on 26 Oct 2026.